Wells Fargo & Company Arrowhead Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

$433 Billion
Q4 2024

A detailed history of Wells Fargo & Company transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 62,886 shares of ARWR stock, worth $759,662. This represents 0.0% of its overall portfolio holdings.

Number of Shares

62,886

Previous 43,953 43.08%

Holding current value

$759,662

Previous $850,000 39.06%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$17.7 - $26.34 $335,114 - $498,695	18,933 Added 43.08%	62,886 $1.18 Million
Q3 2024 Nov 13, 2024	SELL	$19.36 - $29.54 $48,748 - $74,381	-2,518 Reduced 5.42%	43,953 $850,000
Q2 2024 Aug 13, 2024	BUY	$21.87 - $28.24 $29,283 - $37,813	1,339 Added 2.97%	46,471 $1.21 Million
Q1 2024 May 10, 2024	SELL	$27.21 - $39.48 $195,449 - $283,584	-7,183 Reduced 13.73%	45,132 $1.29 Million
Q4 2023 Feb 09, 2024	SELL	$21.2 - $31.03 $1.1 Million - $1.61 Million	-52,022 Reduced 49.86%	52,315 $1.6 Million
Q3 2023 Nov 13, 2023	SELL	$26.2 - $36.08 $149,680 - $206,125	-5,713 Reduced 5.19%	104,337 $2.8 Million
Q2 2023 Aug 15, 2023	BUY	$25.16 - $41.38 $111,056 - $182,651	4,414 Added 4.18%	110,050 $3.92 Million
Q1 2023 May 12, 2023	SELL	$23.68 - $38.51 $1.18 Million - $1.91 Million	-49,717 Reduced 32.0%	105,636 $2.68 Million
Q4 2022 Feb 13, 2023	SELL	$28.0 - $40.56 $190,904 - $276,538	-6,818 Reduced 4.2%	155,353 $6.3 Million
Q3 2022 Nov 14, 2022	BUY	$29.63 - $48.31 $336,685 - $548,946	11,363 Added 7.53%	162,171 $5.36 Million
Q2 2022 Aug 12, 2022	SELL	$27.79 - $50.61 $1.18 Million - $2.15 Million	-42,463 Reduced 21.97%	150,808 $5.31 Million
Q1 2022 May 16, 2022	SELL	$39.62 - $69.97 $801,037 - $1.41 Million	-20,218 Reduced 9.47%	193,271 $8.89 Million
Q4 2021 Feb 14, 2022	SELL	$58.09 - $82.51 $117,516 - $166,917	-2,023 Reduced 0.94%	213,489 $14.2 Million
Q3 2021 Nov 15, 2021	SELL	$58.38 - $84.96 $565,118 - $822,412	-9,680 Reduced 4.3%	215,512 $13.5 Million
Q2 2021 Aug 16, 2021	SELL	$62.15 - $90.32 $1.71 Million - $2.48 Million	-27,448 Reduced 10.86%	225,192 $18.7 Million
Q1 2021 May 13, 2021	SELL	$61.35 - $90.47 $871,170 - $1.28 Million	-14,200 Reduced 5.32%	252,640 $16.8 Million
Q4 2020 Feb 09, 2021	BUY	$43.82 - $85.37 $1.36 Million - $2.64 Million	30,945 Added 13.12%	266,840 $20.5 Million
Q3 2020 Nov 05, 2020	SELL	$33.21 - $51.27 $816,467 - $1.26 Million	-24,585 Reduced 9.44%	235,895 $10.2 Million
Q2 2020 Aug 13, 2020	BUY	$26.12 - $43.27 $876,143 - $1.45 Million	33,543 Added 14.78%	260,480 $11.3 Million
Q1 2020 May 14, 2020	BUY	$20.56 - $63.12 $4.67 Million - $14.3 Million	226,937 New	226,937 $6.53 Million

Others Institutions Holding ARWR

# of Institutions

302

Shares Held

95.7M

Call Options Held

523K

Put Options Held

493K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $1.28B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Arrowhead Pharmaceuticals, Inc. Transaction History